Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa
Antimicrobial Agents and Chemotherapy · 10.12.2025 · 69 (12)
DOI: 10.1128/aac.01048-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 10.12.2025. Verfasst von Lucía González-Pinto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hosp…. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Cephalosporins, beta-Lactamases, Anti-Bacterial Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Xunta de Galicia.
Abstract (Originalsprache)
Cefiderocol/xeruborbactam is a novel β-lactam/β-lactamase inhibitor combination in which the siderophore-cephalosporin cefiderocol is paired with xeruborbactam, a broad-spectrum inhibitor that targets class A to D β-lactamases. We evaluated the contribution of Pseudomonas aeruginosa resistance mechanisms to cefiderocol/xeruborbactam susceptibility. A panel of 61 P . aeruginosa PAO1 derivatives was tested, including 20 knockout mutants representing key chromosomal resistance mechanisms (e.g., ampC overexpression, efflux upregulation, porin loss, iron uptake deficiency) and 41 transformants producing major circulating β-lactamases. Xeruborbactam was assessed in combination with cefiderocol and cefepime at 4 and 8 mg/L and compared with taniborbactam. Additionally, 99 cefiderocol-resistant clinical P. aeruginosa isolates were evaluated. Cefiderocol/xeruborbactam retained activity against most P. aeruginosa mutants with chromosomally encoded resistance mechanisms. However, the P. aeruginosa piuC- defective mutant yielded increased cefiderocol minimum inhibitory concentrations (MIC = 2 mg/L), which could not be restored by xeruborbactam. Xeruborbactam significantly increased the activity of cefiderocol against the majority of P. aeruginosa PAO1 transformants, including those producing PER-1, SHV-12, KPC Ω-loop mutants, or NDM variants. Cefiderocol/xeruborbactam was active against IMP-type MBLs (which only weakly hydrolyze cefiderocol), including xeruborbactam-resistant enzymes. Relative to taniborbactam, xeruborbactam-based combinations showed similar activity against P. aeruginosa PAO1 transformants, but with slightly higher MIC values when tested against metallo-β-lactamase producers. This MIC increase in xeruborbactam-based combinations was partly because of the constitutive MexAB-OprM efflux in the P. aeruginosa background, as confirmed with P. aeruginosa PAO1 efflux mutants. Importantly, xeruborbactam restored susceptibility in 78% of 99 cefiderocol-resistant P. aeruginosa strains, reducing the MIC 90 from 64 to 4 mg/L. Cefiderocol/xeruborbactam shows promising activity against P. aeruginosa .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Microbiología Clínica & Grupo de Investigación en Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Co…
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
- Servicio de Microbiología, Servicio de Microbiología and Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain.
- Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Universidade da Coruña (UDC), A Coruña, Spain.
- Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Besançon, Besançon, France.
- Laboratoire associé au Centre National de Référence de la Résistance aux Antibiotiques, Centre Hospitalier Universitaire de Besançon, Besançon, France.
ORCID-Profile: Lucía González-Pinto, María Antonia Gomis-Font, Gloria Pérez-Rodríguez, Tania Blanco-Martín, Salud Rodríguez-Pallares, Lucía Sánchez-Peña, Alejandro Beceiro, Germán Bou, Katy Jeannot, Antonio Oliver, Jorge Arca-Suárez
Förderung
- Instituto de Salud Carlos III
- Xunta de Galicia
Zitieren
APA
González-Pinto, L., Gomis-Font, M. A., Pérez-Rodríguez, G., Blanco-Martín, T., Rodríguez-Pallares, S., Sánchez-Peña, L., Beceiro, A., Bou, G., Jeannot, K., Oliver, A., & Arca-Suárez, J. (2025). Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 69(12). https://doi.org/10.1128/aac.01048-25
Vancouver
González-Pinto L, Gomis-Font MA, Pérez-Rodríguez G, Blanco-Martín T, Rodríguez-Pallares S, Sánchez-Peña L, et al. Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2025;69(12). doi:10.1128/aac.01048-25
BibTeX
@article{GonzlezPinto2025,
author = {González-Pinto, Lucía and Gomis-Font, María Antonia and Pérez-Rodríguez, Gloria and Blanco-Martín, Tania and Rodríguez-Pallares, Salud and Sánchez-Peña, Lucía and Beceiro, Alejandro and Bou, Germán and Jeannot, Katy and Oliver, Antonio and Arca-Suárez, Jorge},
title = {Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {12},
doi = {10.1128/aac.01048-25}
}
EUVIMED